Ginkgo Bioworks Holdings, Inc.
DNA
$7.54
-$0.27-3.46%
| Weiss Ratings | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.16 | |||
| Price History | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -17.23% | |||
| 30-Day Total Return | -42.79% | |||
| 60-Day Total Return | -35.33% | |||
| 90-Day Total Return | -5.04% | |||
| Year to Date Total Return | -26.22% | |||
| 1-Year Total Return | -84.29% | |||
| 2-Year Total Return | -85.50% | |||
| 3-Year Total Return | -94.54% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -84.75% | |||
| 52-Week Low % Change | 48.48% | |||
| Price | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $51.20 | |||
| 52-Week Low Price | $5.26 | |||
| 52-Week Low Price (Date) | Sep 10, 2024 | |||
| 52-Week High Price (Date) | Mar 08, 2024 | |||
| Valuation | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 424.60M | |||
| Enterprise Value | 330.78M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -10.63 | |||
| Earnings Per Share Growth | -42.20% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.85 | |||
| Price/Book (Q) | 0.59 | |||
| Enterprise Value/Revenue (TTM) | 1.46 | |||
| Price | $7.54 | |||
| Enterprise Value/EBITDA (TTM) | -0.80 | |||
| Enterprise Value/EBIT | -0.69 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 53.81M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 877 422 5362 | |||
| Address | 27 Drydock Avenue Boston, MA 02210 | |||
| Website | www.ginkgo.bio | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -210.82% | |||
| Profit Margin | -240.93% | |||
| Management Effectiveness | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.66% | |||
| Return on Equity | -- | |||
| Income Statement | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 227.04M | |||
| Total Revenue (TTM) | 227.04M | |||
| Revenue Per Share | $4.22 | |||
| Gross Profit (TTM) | 182.50M | |||
| EBITDA (TTM) | -415.65M | |||
| EBIT (TTM) | -478.67M | |||
| Net Income (TTM) | -547.03M | |||
| Net Income Avl. to Common (TTM) | -547.03M | |||
| Total Revenue Growth (Q YOY) | 26.16% | |||
| Earnings Growth (Q YOY) | 49.20% | |||
| EPS Diluted (TTM) | -10.63 | |||
| EPS Diluted Growth (Q YOY) | 53.37% | |||
| Balance Sheet | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 561.57M | |||
| Cash Per Share (Q) | $10.44 | |||
| Total Current Assets (Q) | 602.74M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 716.06M | |||
| Current Ratio (Q) | 5.619 | |||
| Book Value Per Share (Q) | $13.17 | |||
| Total Assets (Q) | 1.38B | |||
| Total Current Liabilities (Q) | 107.27M | |||
| Total Debt (Q) | 467.76M | |||
| Total Liabilities (Q) | 661.39M | |||
| Total Common Equity (Q) | 716.06M | |||
| Cash Flow | DNA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -62.24M | |||
| Cash from Financing (TTM) | -1.74M | |||
| Net Change in Cash (TTM) | -383.84M | |||
| Levered Free Cash Flow (TTM) | -232.57M | |||
| Cash from Operations (TTM) | -319.59M | |||
